title: An open trial of olanzapine in anorexia nervosa.
abstract: BACKGROUND
  Recent reports raise the possibility that olanzapine can assist weight gain and improve behavioral symptoms during refeeding in anorexia nervosa.
  
  
  METHODS
  Seventeen DSM-IV anorexia nervosa subjects hospitalized between May 1999 and October 2000 were enrolled in open-label treatment with olanzapine for up to 6 weeks. Baseline weight and symptoms were compared to patients' status at the end of treatment.
  
  
  RESULTS
  Olanzapine administration was associated with a significant reduction in depression, anxiety, and core eating disorder symptoms, and a significant increase in weight. A comparison with our historical data suggests that subjects in this study had a significantly greater decrease in depression.
  
  
  CONCLUSIONS
  These data lend support to the possibility that olanzapine may be useful in treating anorexia nervosa. However, a controlled trial is necessary to demonstrate that olanzapine is efficacious.
authors.affiliation: Department of Psychiatry, University of Pittsburgh Medical School, Anorexia and Bulimia Nervosa Research Module, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA.
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Barbarich
authors.forename: Claire W
authors.initials: CW
authors.lastname: McConaha
authors.forename: Jill
authors.initials: J
authors.lastname: Gaskill
authors.forename: Maria
authors.initials: M
authors.lastname: La Via
authors.forename: Guido K
authors.initials: GK
authors.lastname: Frank
authors.forename: Sarah
authors.initials: S
authors.lastname: Achenbach
authors.forename: Katherine H
authors.initials: KH
authors.lastname: Plotnicov
authors.forename: Walter H
authors.initials: WH
authors.lastname: Kaye
mesh_terms: D000328:Adult; D000856:Anorexia Nervosa / Q000188:drug therapy* / Q000523:psychology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001526:Behavioral Symptoms / Q000188:drug therapy; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077152:Olanzapine; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine